Deficient expression of BLNK, an adaptor molecule crucial for normal B-cell development, is associated with increased pro-B/ pre-B-cell expansion in mice. It has been proposed that BLNK deficiency is a primary cause of B-lineage acute lymphoblastic leukemia (ALL). We studied BLNK expression in the leukemic cells from 352 patients with childhood ALL ( These results indicate that BLNK deficiency is a rare occurrence in childhood B-lineage ALL and is unlikely to be a common leukemogenic event as previously proposed.
Introduction
The adaptor protein BLNK (also called SLP-65 and BASH) coordinates pre-B-and B-cell-receptor signaling. 1 BLNK activity is indispensable for normal B-cell development: BLNK deficiency hinders the transition of early B-cell progenitors ('pro-B cells') to precursor B cells ('pre-B cells') and markedly reduces B-lymphocyte numbers. [2] [3] [4] [5] BLNK deficiency is one of the causes of agammaglobulinemia in man. 2 Recent reports indicated that BLNK deficiency might also disrupt B-cell homeostasis and result in an abnormal expansion of immature B cells. [6] [7] [8] Flemming et al 6 observed that three of 45 BLNK À/À mice developed pre-B cell tumors. Jumaa et al 7 reported that injection of BLNK À/À murine pre-B cells in immunodeficient mice induced splenomegaly and leukemia, whereas injection of cells with restored BLNK did not. This study also provided a crucial link between BLNK deficiency and leukemogenesis in humans: in 16 of 34 patients with childhood B-lineage acute lymphoblastic leukemia (ALL; a clonal expansion of pro-B/pre-B cells), 9 ,10 leukemic cells reportedly had absent or drastically reduced BLNK transcript and/or protein expression compared to those of healthy B cells. 7 These authors concluded that loss of BLNK is one of the primary causes of childhood B-lineage ALL.
To validate this important assertion, we determined the prevalence of BLNK deficiency in a large and representative cohort of patients with childhood B-lineage ALL. We used a variety of methods to probe BLNK transcript and protein expression in leukemia samples obtained from 352 patients with childhood ALL.
Materials and methods

Patients and cells
We studied bone marrow or peripheral samples obtained at diagnosis from 352 patients with childhood ALL (309 B-lineage; 43 T-lineage). Normal bone marrow and peripheral blood cells were from healthy donors. Protocols had institutional review board approval, and informed consent was obtained as appropriate.
Mononucleated cells were obtained by density gradient separation and cryopreserved. Normal bone marrow CD19 þ
CD10
þ cells and peripheral blood CD19 þ B cells were enriched by fluorescence activated and magnetic cell sorting, respectively; cell purity exceeded 95%. The B-lineage ALL cell lines RS4;11, REH, OP-1, KOPN57bi, 380, Nalm6 and 697, the Epstein-Barr virus (EBV) þ mature B-cell lines Raji, AG8-0 Cord and A.D., the T-cell line Jurkat, and the myeloid cell line K562 were available in our laboratory.
BLNK transcript expression
Global gene expression analysis of ALL samples was previously described. 11, 12 cDNA was hybridized to HG_U95Av2 or to HG_U133A GeneChip arrays (Affymetrix, Santa Clara, CA, USA). The expression of each gene (present, marginal or absent) was calculated using Affymetrix Microarray suite 5.0 (MAS 5.0). Detection values were determined by default parameters, and signal values were scaled by global methods to a value of 500.
For reverse transcriptase-polymerase chain reaction (RT-PCR), cDNA was obtained by reverse transcription of RNA with random hexamers and amplified using the following primers: BLNK exons 1-7: sense 5 0 -TGGACAGTTATTCGTGTCTCTT-3 0 ; antisense 5 0 -GTGAACTGC TTTCTGTGGGA-3 0 ; BLNK exons 8-17: sense 5 0 -TCAACCAAGCCAAATTCCTC-3 0 ; antisense 5 0 -CTTTGGGAAAGTGTCTGAAGC-3 0 . Real-time PCR was performed using BLNK-specific primers and an ABI Prism 7700 Sequence Detector (Applied Biosystems; Foster City, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase was used as a reference.
BLNK protein expression
For Western blotting, cell lysates were separated by SDS-PAGE on a 7.5% acrylamide gel. Transfer membranes were incubated with mouse anti-human BLNK (2B11; Santa Cruz, Santa Cruz, CA, USA) and goat anti-mouse IgG conjugated to horseradish peroxidase, and processed with the ECL kit (Pharmacia, Piscataway, NJ, USA). For flow cytometry, cells were labeled with the anti-BLNK antibody (of IgG2a class) followed by goat antimouse IgG2a conjugated to fluorescein isothiocyanate (Jackson Research Laboratories, West Grove, PA, USA) after surface membrane permeabilization of cells labeled with anti-CD19 (of IgM class; Research Diagnostics Incorporated, Flanders, NJ, USA) and goat-anti mouse IgM conjugated to phycoerythin (PE; Southern Biotechnology Associates, Birmingham, AL, USA). BLNK staining was also combined with anti-CD19 allophycocyanin, anti-CD34 peridinin chlorophyll protein and anti-CD10 PE, all of IgG1 class (Becton Dickinson, San Jose, CA, USA). Cells were analyzed with a FACScalibur flow cytometer and the Cell Quest software (Becton Dickinson). BLNK levels did not correlate with ALL genetic subgroups (Figure 1a) , or differentiation stage (pro-B vs pre-B; not shown).
Results and discussion
With primers spanning BLNK exons 1-7, all seven B-lineage ALL cell lines and 15 primary B-lineage ALL from the group studied with microarrays expressed BLNK transcripts at levels similar to those of mature EBV þ B cells and healthy CD19 þ peripheral blood B cells (Figure 1b and c) . Median percent leukemic cells (CD10 þ , CD19 þ and/or TdT þ ) in the ALL samples was 96% (range 90-99%); median percent CD14 þ monocytes was o1%. Therefore, BLNK expression in these samples cannot be ascribed to non-leukemic cells. To ensure that expression of BLNK was not limited to exon 1-7 fragments, we repeated RT-PCR using primers spanning exons 8-17, thus covering the entire BLNK sequence. Again, all B-lineage ALL cell lines and primary samples expressed BLNK transcripts. BLNK expression was confirmed by 'real-time' PCR in nine primary B-lineage ALL: it exceeded (by a factor of 2-14) levels measured in two EBV þ cell lines. Expression of BLNK in Blineage ALL was further confirmed by independent RT-PCR studies performed in another laboratory using the exon 1-7 primers: BLNK transcripts were detectable in all 15 B-lineage ALL samples. Collectively, all 30 B-lineage ALL examined by RT-PCR expressed BLNK.
BLNK transcripts appeared as a single band of approximately 630 base pairs (Figure 1 ). We observed an additional band with primers matching exons 1, 3b and 7 only when PCR was extended to 60 cycles instead of the typical 30 cycles. According to its sequence, this band probably corresponds to the alternative BLNK transcript containing exon 3b described by Jumaa et al. 7 However, this transcript was also seen in normal B cells. Therefore, we interpret it as an alternative splicing product of BLNK expressed at extremely low levels in B cells. We cannot exclude that dominant aberrant BLNK transcripts may occur in some ALL cases, 7 but none of the cases that we studied had this feature. Expression of BLNK transcripts resulted in BLNK protein with intact immunogenic properties. By Western blotting, seven Blineage ALL cell lines and nine patient samples expressed BLNK at levels similar to that of EBV þ B cells (Figure 2a ). In 10 additional B-lineage ALL samples studied by flow cytometry, leukemic lymphoblasts were uniformly BLNK þ . These results, together with the microarray and RT-PCR data, indicate that BLNK is consistently expressed in B-lineage ALL. BLNK expression levels in B-lineage ALL cells were similar to those detected in normal CD19
þ bone marrow cells from two healthy donors (Figure 2b ). Among normal CD19 þ cells, BLNK was expressed at all stages of maturation, irrespective of CD10 or CD34 expression. Therefore, BLNK expression is a marker of B-cell commitment that is maintained during leukemogenesis. B-lineage ALL cells are frozen at an early B-cell differentiation stage and BLNK is essential for normal B-cell differentiation. Therefore, the notion that BLNK deficiency may play a role in leukemogenesis is attractive. Our results, however, indicate that the block of B-cell differentiation characteristic of B-lineage ALL cannot be attributed to deficient BLNK expression in the vast majority of cases. It is known that B-lineage ALL cells may overor underexpress a multitude of molecules when compared to their normal counterparts. [13] [14] [15] In the rare cases with undetectable BLNK expression, the link between BLNK deficiency, genetic abnormalities characteristic of ALL and leukemogenesis remains to be elucidated.
